MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc.
Your view on MIRA
Overview
What the company does, where it operates, and who runs it.
About MIRA Pharmaceuticals, Inc.
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Erez Aminov
- Headquarters
- 855 North Wolfe Street, Baltimore, MD, US
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Erez Aminov
- Headquarters
- 855 North Wolfe Street, Baltimore, MD, US
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company.
The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia.
It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for MIRA Pharmaceuticals, Inc., and the rating behind it. MIRA last traded at $0.91; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for MIRA Pharmaceuticals, Inc.. Starting points for MIRA Pharmaceuticals, Inc.: EPS -$0.23, beta 1.53 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for MIRA Pharmaceuticals, Inc.. MIRA Pharmaceuticals, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for MIRA Pharmaceuticals, Inc.. Trailing twelve-month EPS for MIRA Pharmaceuticals, Inc. stands at -$0.23. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for MIRA Pharmaceuticals, Inc.. MIRA Pharmaceuticals, Inc. has reported as a listed company since 2023. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
MIRA Pharmaceuticals, Inc. valued side by side against its closest peers. MIRA Pharmaceuticals, Inc. is measured against Drug Manufacturers - General peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold MIRA Pharmaceuticals, Inc., and how their positions are changing. At a $38.1M market value, institutional positions materially move MIRA Pharmaceuticals, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by MIRA Pharmaceuticals, Inc. executives and directors. Shares of MIRA Pharmaceuticals, Inc. have traded between $0.73 and $2.45 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming MIRA Pharmaceuticals, Inc.. MIRA Pharmaceuticals, Inc. is a $38.1M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming MIRA Pharmaceuticals, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for MIRA Pharmaceuticals, Inc.. Coverage tracks MIRA Pharmaceuticals, Inc. within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.